1 Min Read
May 26 (Reuters) - Novartis Ag
* Novartis receives FDA approval for expanded use of zykadia® in first-line alk-positive metastatic non-small cell lung cancer (nsclc) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.